Anhui Provincial Hospital
Anhui Provincial Hospital
Hefei, China34 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders | Optic Neuromyelitis Spectrum Disease | Active, not recruiting | Phase 2 | 2026-10-02 | NCT06044350 | |
| Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | Resectable Esophageal Squamous Cell Carcinoma | Active, not recruiting | Phase 3 | 2026-09-17 | NCT05043688 | |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-15 | NCT06899126 | |
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Active, not recruiting | Phase 3 | 2026-09-08 | NCT07663903 | |
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Active, not recruiting | Phase 3 | 2026-09-04 | NCT07684898 | |
| A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-08-20 | NCT06741644 | |
| A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Not yet recruiting | Phase 2 | 2026-06-30 | NCT07677514 | |
| A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-05-26 | NCT05668988 | |
| A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Recruiting | Phase 2 / Phase 3 | 2026-05-05 | NCT06413654 | |
| A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors | Advanced/Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-04-15 | NCT05718895 | |
| Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 3 | 2026-03-17 | NCT05738694 | |
| Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-09 | NCT04639986 | |
| The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 2 / Phase 3 | 2026-01-30 | NCT06921486 | |
| A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC | TNBC | Enrolling by invitation | Phase 2 | 2026-01-29 | NCT07376629 | |
| A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev | Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, thrombotic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-01-15 | NCT04649489 | |
| A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2025-11-19 | NCT04982237 | |
| Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2025-10-02 | NCT05531526 | |
| A Clinical Study of HMPL-506 in Patients With Hematological Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 1 | 2025-09-29 | NCT06387082 | |
| JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2025-09-12 | NCT06079983 | |
| A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2025-08-03 | NCT05485948 | |
| CAR-T Cells Therapy for Patients With Autoimmune Diseases | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, skin disorder, systemic lupus erythematosus, systemic sclerosis | Recruiting | Not applicable | 2025-07-08 | NCT07052565 | |
| Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer | hepatocellular carcinoma | Not yet recruiting | Not stated | 2025-06-05 | NCT07007286 | |
| A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | SCLC | Active, not recruiting | Phase 2 | 2025-03-12 | NCT05844150 | |
| Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Advanced Renal Cell Carcinoma | Active, not recruiting | Phase 2 / Phase 3 | 2025-01-03 | NCT05522231 | |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active, not recruiting | Phase 3 | 2024-12-31 | NCT04691804 |